All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99


Relative Articles


Ultrasonographic Changes of Adrenal Glands Size under Trilostane Therapy, Their Correlation with Clinical Signs and Endocrine Tests and Possibility of Introducing Ultrasound as Additional Monitoring Modality of Cushing’s Syndrome

DOI: 10.4236/ojvm.2022.127007, PP. 57-70

Keywords: Adrenal Gland, Ultrasonography, Trilostane, Monitoring

Full-Text   Cite this paper   Add to My Lib


A prospective study of 15 dogs with diagnosed Cushing’s syndrome was made to find a correlation between adrenal size enlargement, clinical signs and results of an ACTH stimulation test. To our knowledge, no study was made trying to correlate changes in adrenal size, response to therapy and ACTH stimulation test results. Ultrasonographic evaluation and an endocrine test (ACTH stimulation test/“pre pill”) were performed in each dog two weeks after initiating the therapy, two to four weeks after changing the dosage of trilostane and ideally 10 weeks after establishing the right dosage of trilostane (two owners showed up later on date due pandemic of COVID-19). The results indicate that there is correlation between adrenal size enlargement and response to trilostane therapy. In this study, all dogs that had increase in adrenal gland size of more than 7% showed as well clinical improvement of HAC (hyperadrenocorticism) signs under trilostane therapy. Further, possible multicentric, studies should be performed to verify assumed correlation between adrenal size enlargement and positive response to trilostane therapy.


[1]  Ruckstuhl, N.S., Nett, C.S. and Reusch, C.E. (2002) Results of Clinical Examinations, Laboratory Tests, and Ultrasonography in Dogs with Pituitary-Dependent Hyperadrenocorticism Treated with Trilostane. American Journal of Veterinary Research, 63, 506-512.
[2]  Mantis, P., Lamb, C.R., Witt, A.L. and Neiger, R. (2003) Changes in Ultrasonographic Appearance of Adrenal Glands in Dogs with Pituitary Dependent Hyperadrenocorticism Treated with Trilostane. Veterinary Radiology & Ultrasound, 44, 682-685.
[3]  Pey, P., Daminet, S., Smets, P. and Saunders, J. (2012) Contrast Enhanced Ultrasonography in Dogs with Acth Dependent Hyperadrenocorticism Receiving Trilostane Treatment: A Preliminary Study. Veterinary Radiology & Ultrasound, 54, 408-449
[4]  Melian, C., Pérez-López, L., Saavedra-Santana, P., García, A.G., Santos, Y. and Jaber, J. (2021) Ultrasound Evaluation of Adrenal Gland Size in Clinically Healthy Dogs and in Dogs with Hyperadrenocorticism. The Veterinary Record, 188, Article No. e80.
[5]  Hoffrogge, S. (2017) Einflussfaktoren auf den Dexamethason-Suppressionstest beim Hund und möglicher Einsatz des Cortisol/Dehydroepiandrosteron-Verhältnisses in der Cushing-Diagnostik 2017. Dissertation, Tierärztliche Hochschule Hannover, Hannover.
[6]  Behrend, E.N., Kooistra, H.S., Nelson, R., Reusch, C.E. and Scott-Moncrieff, J.C. (2013) Diagnosis of Spontaneous Canine Hyperadrenocorticism: 2012 ACVIM Consensus Statement. Journal of Veterinary Internal Medicine, 27, 1292-1304.
[7]  Carvalho, M.A., Leal, R., Pérez-Alenza, M.D., Arenas, C., Golinelli, S., Fracassi, F., et al. (2021) Diagnosis of Naturally Occurring Hypercortisolism by Primary Care Veterinarians: A Western European Survey.
[8]  Church, D.B., Nicholson, A.I., Ilkiw, J.E. and Emslie, D.R. (1994) Effect of Non-Adrenal Illness, Anaesthesia and Surgery on Plasma Cortisol Concentrations in Dogs. Research in Veterinary Science, 56, 129-131.
[9]  Kaplan, A.J., Peterson, M.E. and Kemppainen, R.J. (1995) Effects of Disease on the Results of Diagnostic Tests for Use in Detecting Hyperadrenocorticism in Dogs. Journal of the American Veterinary Medical Association, 207, 445-451.
[10]  Guptill, L., Scott-Moncrieff, J.C. and Widmer, W.R. (1997) Diagnosis of Caninehyperadrenocorticism. Veterinary Clinics of North America: Small Animal Practice, 27, 215-235.
[11]  Hoffrogge, S., Schmicke, M. and Mischke, R. (2016) Duration of Blood Plasma Cortisol Suppression after a Low-Dose Dexamethasone Suppression Test in Dogs. Comparative Clinical Pathology, 25, 299-303.
[12]  Zeugswetter, F.K., Carranza Valencia, A., Glavassevich, K. and Schwendenwein, I. (2021) Patterns of the Low-Dose Dexamethasone Suppression Test in Caninehyperadrenocorticism Revisited. Veterinary Clinical Pathology, 50, 62-70.
[13]  Monroe, W.E., Panciera, D.L. and Zimmerman, K.L. (2012) Concentrations of Noncortisol Adrenal Steroids in Response to ACTH in Dogs with Adrenal-Dependent Hyperadrenocorticism, Pituitary-Dependent Hyperadrenocorticism, and Nonadrenal Illness. Journal of Veterinary Internal Medicine, 26, 945-952.
[14]  Hoffrogge, S., Fels, L., Schmicke, M. and Mischke, R. (2017) Atypical Cushing’s Syndrome in a Dog. A Case Report. Tierärztliche Praxis, 45, 186-192.
[15]  Golinelli, S., Tardo, A.M. and Fracassi, F. (2020) Medical Treatment and Therapeutic Monitoring Options in Dogs with Cushing’s Syndrome. Veterinaria, 34, 207-219.
[16]  Golinelli, S., de Marco, V., Leal, R.O., Barbarossa, A., Aniballi, C., Maietti, E., et al. (2021) Comparison of Methods to Monitor Dogs with Hypercortisolism Treated with Trilostane. Journal of Veterinary Internal Medicine, 35, 2616-2627.
[17]  Sanders, K., Kooistra, H.S. and Galac, S. (2018) Treating Canine Cushing’s Syndrome: Current Options and Future Prospects. The Veterinary Journal, 241, 42-51.
[18]  Plumb, D.C. (2008) Trilostane. In: Plumb, D.C., Ed., Veterinary Drug Handbook, 6th Edition, Blackwell Publishing Professional, Ames, 907-908.
[19]  Feldman, E.C., Nelson, R.W., Reusch, C.E. and Scott-Moncrieff, J.C.R. (2015) Endocrinology, 4th Edition, Elsevier Saunders, St Louis, 377-451.
[20]  Bell, R., Neiger, R., McGrotty, Y. and Ramsey, I.K. (2006) Study of the Effects of Once Daily Doses of Trilostane on Cortisol Concentrations and Responsiveness to Adrenocorticotrophic Hormone in Hyperadrenocorticoid Dogs. Veterinary Record, 159, 277-281.
[21]  Bermejo, C.A., Perez-Alenza, M.D., San Josè, P.G., Llauet, L., Pérez-López, L., Melián, C., et al. (2020) Laboratory Assessment of Trilostane Treatment in Dogs with Pituitary Dependent Hyperadrenocorticism. Journal of Veterinary Internal Medicine, 34, 1413-1422.
[22]  Midence, I.N., Drobatz, K.J. and Hess, R.S. (2015) Cortisol Concentrations in Well Regulated Dogs with Hyperadrenocorticism Treated with Trilostane. Journal of Veterinary Internal Medicine, 29, 1529-1533.
[23]  Bonadio, C.M., Feldman, E.C., Cohen, T.A. and Kass, P.H. (2014) Comparison of Adrenocorticotropic Hormone Stimulation Test Results Started 2 versus 4 Hours after Administration in Dogs with Naturally Occurring Hyperadrenocorticism. Journal of Veterinary Internal Medicine, 28, 1239-1243.
[24]  Griebsch, C., Lehnert, C., Williams, G.J., Failing, K. and Neiger, R. (2014) Effect of Trilostane on Hormone and Serum Electrolyte Concentrations in Dogs with Pituitary Dependent Hyperadrenocorticism. Journal of Veterinary Internal Medicine, 28, 160-165.
[25]  Ramsey, I.K., Fracassi, F., Galac, S., Macfarlane, L. and Reusch, C.E. (2017) The Repeatability of Various Cortisol Measurements in Clinically Stable Dogs with Hyperadrenocorticism Being Treated with Trilostane. Oral Research Communication of the 26th ECVIM-CA Congress.
[26]  Macfarlane, L., Parkin, T. and Ramsey, I. (2016) Pre Trilostane and Three-Hour Post Trilostane Cortisol to Monitor Trilostane Therapy in Dogs. Veterinary Record, 179, 597.
[27]  Boretti, F., Musella, C., Burkhardt, W., Kuemmerle-Fraune, C., Round, B., Reusch, C. and Sieber-Ruckstuhl, N. (2018) Comparison of Two Pre Pill Cortisol Concentrations in Dogs with Hypercortisolism Treated with Trilostane. BMC Veterinary Research, 14, Article No. 417.
[28]  Burkhardt, W.A., Guscetti, F., Boretti, F.S., Ivos Todesco, A., Aldajarov, N., Lutz, T.A., Reusch, C.E. and Sieber-Ruckstuhl, N.S. (2011) Adrenocorticotropic Hormone, but Not Trilostane, Causes Severe Adrenal Hemorrhage, Vacuolization, and Apoptosis in Rats. Domestic Animal Endocrinology, 40, 155-164.
[29]  Sieber-Ruckstuhl, N.S., Boretti, F.S., Wenger, M., Maser-Gluth, C. and Reusch, C.E. (2006) Cortisol, Aldosterone, Cortisol Precursor, Androgenand Endogenous ACTH Concentrations in Dogs with Pituitary-Dependant Hyperadrenocorticism Treated with Trilostane. Domestic Animal Endocrinology, 31, 63-75.
[30]  Teshima, T., Hara, Y., Takekoshi, S., Nezu, Y., Harada, Y., Yogo, T., Teramoto, A., Osamura, R.Y. and Tagawa, M. (2009) Trilostane-Induced Inhibition of Cortisol Secretion Results in Reduced Negative Feedback at the Hypothalamic-Pituitary Axis. Domestic Animal Endocrinology, 36, 32-44.


comments powered by Disqus

Contact Us


WhatsApp +8615387084133

WeChat 1538708413